Vigabatrin Visual Toxicity: Evolution and Dose Dependence
Open accessThe DOI matches its Crossref record.
Abstract
Summary: Purpose: To investigate the prevalence and prognosis of visual field defects (VFDs) in epilepsy patients with and without vigabatrin (VGB) treatment; to investigate the possible relationship between VFDs and cumulative VGB dose, and to characterise the evolution of VFDs. Methods: A cohort of 155 presurgical candidates who had undergone full‐field Goldmann perimetry (GP) was studied, 99 (64%) of whom had been treated with VGB. All GPs were reevaluated in 1998 by one experienced examiner, blinded to medication. Duration of treatment and total VGB dose were related to perimetric results. Results: Twenty‐five (16%) of the 155 patients had VFDs: Nineteen (19%) of the 99 VGB‐treated patients, and six (11%) of the 56 patients unexposed to VGB. VGB‐treated patients with VFDs had been treated significantly longer than those without VFDs. Cumulative VGB dose could be calculated for 84 patients. The prevalence of VFDs increased significantly with increasing total VGB‐dose, from 4% in the 51 patients who had been exposed to ≤1 kg VGB, to 75% in the eight patients with a total dose of 3–5 kg of VGB. Sixteen VGB‐treated patients were reexamined 2–10 years later. In the 12 where evaluation was possible, all still had VFDs, which had worsened in five cases (42%) and improved in none. Conclusions: This study indicates a strong relationship between VFDs and duration and total dose of VGB. VFDs were irreversible and in a substantial percentage progressive. Similar VFDs may, however, also be found in patients unexposed to VGB. A model of the evolution of the VFDs in VGB toxicity is introduced, and a new simple visual field test is proposed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Northrup, H., Aronow, M. E., Bebin, E. M., Bissler, J., Darling, T. N., de Vries, P. J., Frost, M. D., Fuchs, Z., Gosnell, E. S., Gupta, N., et al. (2021) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2021.07.011 · Cited by 736
Wilby, J., Kainth, A., Hawkins, N., Epstein, D., McIntosh, H., McDaid, C., Mason, A., Golder, S., O'Meara, S., Sculpher, M., et al. (2005) · Health Technology Assessment · doi:10.3310/hta9150 · Cited by 271
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
Focal neurometabolic alterations in mice deficient for succinate semialdehyde dehydrogenase
Gibson, K. M., Schor, D. S. M., Gupta, M., Guerand, W. S., Senephansiri, H., Burlingame, T. G., Bartels, H., Hogema, B. M., Bottiglieri, T., Froestl, W., et al. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00784.x · Cited by 55
“intervention has recently been linked to visual field defects (Gross-Tsur et al. 2000; Malmgren et al. 2001).”
BackgroundMurine succinate semialdehyde dehydrogenase deficiency
Gupta, M., Hogema, B. M., Grompe, M., Bottiglieri, T. G., Concas, A., Biggio, G., Sogliano, C., Rigamonti, A. E., Pearl, P. L., Snead, O. C., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10625 · Cited by 50
Metadata
- Authors
- Malmgren, K., Ben‐Menachem, E., & Frisén, L.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2001-05-12
- Volume
- 42
- Issue
- 5
- Pages
- 609-615
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2049214932
- Cited by
- 112
- References
- 0
- FWCI
- 10.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vigabatrin Visual Toxicity: Evolution and Dose Dependence. https://app.cochat.ai/papers/10.1046/j.1528-1157.2001.28600.x
- The paper
- Malmgren, K., Ben‐Menachem, E., & Frisén, L. (2001). Vigabatrin Visual Toxicity: Evolution and Dose Dependence. Epilepsia. https://doi.org/10.1046/j.1528-1157.2001.28600.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.